Emerging role of S-1 in gastric cancer

Item

http://www.wikidata.org/entity/Q26774720

description

2015 nî lūn-bûn

@nan

2015 թուականին հրատարակուած գիտական յօդուած

@hyw

2015 թվականին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Emerging role of S-1 in gastric cancer

@ast

Emerging role of S-1 in gastric cancer

@en

Emerging role of S-1 in gastric cancer

@nl

type

Item

label

Emerging role of S-1 in gastric cancer

@ast

Emerging role of S-1 in gastric cancer

@en

Emerging role of S-1 in gastric cancer

@nl

prefLabel

Emerging role of S-1 in gastric cancer

@ast

Emerging role of S-1 in gastric cancer

@en

Emerging role of S-1 in gastric cancer

@nl

P1476

Emerging role of S-1 in gastric cancer

@en

P2093

Eriseld Krasniqi

http://www.w3.org/2001/XMLSchema#string

Stefania Pellicori

http://www.w3.org/2001/XMLSchema#string

Vincenzo Formica

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

S-1-based vs non-S-1-based chemotherapy in advanced gastric cancer: a meta-analysis

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Fluorinated pyrimidines, a new class of tumour-inhibitory compounds

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study.

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Clinical outcomes of TS-1 chemotherapy for advanced and recurrent gastric cancer.

P304

219-28

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/0971-5851.171542

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26811591

http://www.w3.org/2001/XMLSchema#string

P932

4711220

http://www.w3.org/2001/XMLSchema#string